Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 13, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the resumption of work on the Environmental and Social Impact Assessment ("ESIA") for its 100%-owned Lac Knife flake graphite project located near Fermont, in the province's prolific iron ore mining district.The Company has formally re-engaged IOS Geosciences Inc. ("IOS"), a leading Québec-based geological consulting firm and former general contractor on the ESIA, to complete a total of sixteen (16) technical reports required for submission to Québec's environmental and natural resource authorities. These reports represent a major step in advancing the Lac Knife project toward permitting and the goal of mine construction.The ESIA program, initially launched in 2020, involves multidisciplinary technical evaluations and environmental baseline work conducted across 2020 and 2021. Finalization was delayed due to funding constraints but is now back on track. Report completion is estimated by early 2026, with submissions planned shortly thereafter to the Québec Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), as well as the Ministry of Natural Resources and Forests ("MRNF").The sixteen (16) technical reports in progress cover critical permitting areas, including:Condemnation and pit wall drillingAcid-generating potential analysisGeotechnical drilling and soil mechanicsSoil geochemistry and chemistry baselineLake-bottom geochemical and surface water quality surveysGroundwater habitat assessment and follow-upCaribou habitat assessment and follow-upGeometallurgical and graphite flake characterizationThese comprehensive studies are essential for satisfying Québec's rigorous environmental and social licensing requirements and underscore Focus Graphite's commitment to environmental stewardship and Indigenous engagement through project development.In parallel, Focus has also authorized IOS proceed with geochemical analysis of over 1,000 split and pulverized drill core samples collected from its 2022 exploration drilling program at the Lac Tétépisca ("Tétépisca") graphite project. The samples, targeting the Southwest MOGC and West Limb geophysical (MAG-EM) conductors, will undergo carbon and sulfur determinations at certified laboratories.Upon receipt of assays, IOS will finalize and submit the corresponding technical reports covering 14,900.5 metres of core drilling from 74 holes to the MRNF. An updated Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") and National Instrument ("NI") 43-101 compliant Mineral Resource Estimate ("MRE") for the Manicouagan-Ouest Graphitic Corridor ("MOGC") graphite deposit is anticipated in Fall 2025, which will further define Tétépisca's development potential alongside Lac Knife."Resuming the ESIA is a pivotal milestone that moves us closer to full permitting and our goal of mine development at Lac Knife," said Dean Hanisch, CEO of Focus Graphite. "With most fieldwork and laboratory studies already complete, we're in a strong position to finalize this critical stage efficiently. At the same time, initiating assay work at Tétépisca to support an upgraded mineral resource estimate reflects our commitment to building value across our entire Québec asset base."The Company also announced the grant of incentive stock options as compensation to its directors, officers, employees, and consultants. Options to purchase up to 4,215,000 Common Shares of the Company have been granted at an exercise price of $0.14 per share. The options expire on 13 August, 2030. Additionally, the Company has granted 1,350,000 restricted stock units ("RSUs") to officers, directors, and consultants of the Company under the terms of the Company's restricted share unit and equity incentive plan (the "RSU and EIP Plan"). Each RSU entitles the holder to acquire one common share of the Company after the vesting period in accordance with the Plan.Qualified PersonsThe technical content disclosed in this news release was reviewed and approved by Réjean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the completion and submission of the sixteen technical reports required for the Lac Knife Environmental and Social Impact Assessment, the anticipated timeline for ESIA report submission and permitting, the initiation and results of geochemical analyses at the Lac Tétépisca project, the anticipated updated NI 43-101 Mineral Resource Estimate for the Tétépisca deposit, the Company's positioning as a near- and long-term secure supplier of specialty graphite materials, and the potential geopolitical significance of Canadian graphite supply.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262450 Copyright 2025 ACN Newswire via SeaPRwire.com.

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding. Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

ROMEOVILLE, IL, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, has signed an agreement with Syensqo to distribute its Solef® Polyvinylidene Fluoride (PVDF) materials in North America. The agreement expands access to this critical material known for its combination of chemical resistance and flexibility. Solef® PVDF joins a growing list of high-performance materials in Formerra's portfolio designed to advance product development and innovation."With this new agreement, Formerra will be able to support customers across multiple markets with the materials they need to meet demanding application requirements," said Bob Long, Business Development Manager at Formerra. "In addition, this reinforces our commitment to delivering unmatched access, application support, and advanced materials for customers navigating complex performance and regulatory challenges."PVDF is positioned near the top of the performance pyramid for its outstanding chemical and heat resistance. Its inherent flexibility further enhances its suitability for demanding applications in chemical processing, healthcare, and automotive industries. Key properties* include:Heat resistance: Continuous use temperatures up to 150 degrees C (302 degrees F), bursting pressures of up to 139 bar (2,017 psi) at room temperatureChemical purity: Ultra-pure water resistivity, meeting SEMI F-57 specifications for the semiconductor industryBalance of strength and flexibility: Tensile yield strength up to 55 MPa (8,000 psi) with elongation at break up to 100%"We chose Formerra as our distribution partner for Solef® PVDF in North America because of their technical and commercial reach," said Rose Catherin, Sales Director Americas, Channel partners, Distribution and Digital Sales at Syensqo Specialty Polymers. "Their commitment to excellence and long-standing presence in critical markets make them an ideal fit to help expand the availability and use of Solef® PVDF."*As measured by TDSCaption: Formerra Becomes North American Distributor for Syensqo Solef®PVDF.Key Details:Formerra is an authorized distributor of Solef® PVDF from Syensqo in North America.The agreement includes support for high-performance applications across a broad spectrum of industries.PVDF offers excellent chemical resistance, thermal stability, and flexibility.Formerra provides technical guidance and supply chain expertise to support material selection and application development.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2025 ACN Newswire via SeaPRwire.com.

WESTLAKE, OH, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - GEON® Performance Solutions, a global leader in the formulation, development and manufacture of performance polymer solutions, announced today that it received Great Place To Work® (GPTW) certifications for its USA, Canada, Mexico and China locations. Since partnering with GPTW in 2021, GEON's cultural and sustainability vision is to achieve this recognition each year.GPTW Certified GEON is Great Place to Work-Certified in the US, Canada, Mexico and China.GPTW asks employees to quantify and benchmark their experience, workplace culture and leadership behaviors which are proven to deliver market-leading revenue, employee retention and increased innovation."We are thrilled to receive Great Place To Work recognition in all four countries in which we operate for two consecutive years. Great Place To Work companies are evaluated against top employers globally, so this is a testament that our journey to cultural excellence is on the right track," said GEON Chief Executive Officer Tracy Garrison. "We believe leaders in the marketplace must also be leaders in the workplace. To do this, we nurture a positive work culture everywhere we operate while striving to grow in areas that still need improvement."GEON received a 79 percent engagement rating which exceeds the typical company by over 20 percent. GEON's score improved year-over-year in the U.S., Canada and China and held steady in Mexico. The U.S. survey included the full scope of GEON employees, including employees from Foster, LLC which GEON acquired in January of 2025.According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a Certified™ great workplace. Additionally, employees at Certified workplaces are 93 percent more likely to look forward to coming to work and are twice as likely to be paid fairly and have a fair chance at promotion."Like the data show, achieving GPTW certification is not only a reflection of our culture, but it directly impacts our ability to retain good people who are excited to come to work each day," said GEON Chief Human Resources Officer Jerome Beguerie. "This has a direct impact on our customers and their experience with us."About GEON Performance SolutionsGEON® Performance Solutions is a leading innovator in the development of polymer compounding solutions for a broad range of markets including building & infrastructure, consumer, industrial, transportation, and power & communications. With the acquisition of Foster, LLC, GEON has enhanced participation in the high-growth healthcare and medical device industry and builds on a portfolio of highly adaptable vinyl, polyolefin and engineered resin technologies as well as a full-service contract manufacturing business. GEON has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. GEON is a portfolio company of SK Capital Partners.About SK CapitalSK Capital is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.Contact InformationRenita AndersonVice President, Marketing & Business Developmentrenita.anderson@geon.com678-772-8953SOURCE: GEON Performance Solutions Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - China Lilang Limited (“China Lilang” or the “Company”, together with its subsidiaries, the “Group”; stock code: 1234) today announced its interim results for the six months ended 30 June 2025.Mr. Wang Dong Xing, Chairman and Non-Executive Director of China Lilang, said: “In the first half of 2025, international trade environment became increasingly harsh and complex. During the period, consumer spending in the mainland gradually recovered, but consumers remained cautious about spending on non-essential goods. China Lilang prides a well-differentiated brand matrix that has enabled it to penetrate and have a strong foothold in the menswear market. It appealed to its target customer base through precise product positioning and channel strategies, and launched a number of ‘LILANZ’ and ‘LESS IS MORE’ brand products to meet the needs of the consumer market. In addition, the Group actively deployed omni-channel marketing to enhance the popularity of the Lilang brands and improve the efficiency of online and offline sales channels to boost overall sales and operational competence.”For the six months ended 30 June 2025, the Group’s revenue increased by 7.9% to RMB1,727 million. Among this, revenue of the smart causal collection and other collections urged 31.8%, mainly driven by strong performance in in-store sales of the smart casual collection and new retail business. The core collection recorded a slight decrease of 0.2%, primarily due to one-off revenue deduction resulting from the promotion of DTC business model in Shandong Province and Chongqing City.Gross profit margin increased by 0.2 percentage points year-on-year to 50.2%, mainly due to the increase in average unit price as a result of higher proportion of the direct-to-retail operation in sales revenue. Profit attributable to equity shareholders for the period was RMB242.5 million (2024 Interim: RMB280.1 million). Profit margin attributable to equity shareholders was 14.0%. Earnings per share were RMB20.2 cents.During the period, the Group maintained a healthy financial position with sufficient cash flow. The Board of Directors has recommended payment of an interim dividend of HK11 cents (2024 Interim: HK13 cents) per ordinary share and a special interim dividend of HK5 cents (2024 Interim: HK5 cents) per ordinary share, thereby maintaining a stable payout ratio.The Group diligently advanced its strategic transformation during the period, plus continued to implement its “Multi-brands and Internationalization” development strategy to expand business. The core collection “LILANZ” has continued to consolidate its competitive advantage in the traditional menswear market and successfully amplified its brand awareness and market share. The repurchase and transformation of distribution and agency rights in North-Eastern China and Jiangsu Province were completed last year. During the period, the Group has repurchased the operating rights from distributors in the entire Shandong province and Chongqing city and adopted the DTC model. The "LESS IS MORE" smart casual collection that targets younger consumers continued to operate in a fully direct-to-retail mode. The newly opened stores of the smart casual collection were mainly in South-Western China and Central and Southern China. As at 30 June 2025, there were 2,443 stores for the core collection and 331 stores for the smart casual collection.During the period, the Group continued to optimize its sales channels, opening new stores in shopping malls and outlet stores in prime locations as planned. By incorporating tech-savvy visual aesthetics and youthful, fashionable layouts, the Group has brought the brand’s“Simplicity but not Simple” philosophy to life, thereby enhancing its brand image and driving sales. As at June 30, 2025, the number of stores located in shopping malls rose to 957 (31 December 2024: 933), the store count of outlet stores increased to 121 (31 December 2024: 103), with a total of 2,774 retail stores.The Group completed strategic transformation of its new retail business, upgrading it from an inventory clearance channel into a major new product sales platform, which reported a remarkable 24.6% increase in revenue for the period. While continuing to strengthen its presence on established sales platforms like Tmall, JD.com and TikTok, the Group has also expanded into emerging channels such as Pinduoduo, Wechat Channels and Poizon, creating diversified online sales network all together. It has kept enhancing its e-commerce strategy and leveraged social media platforms such as Xiaohongshu and Weibo to keep releasing high-quality content. This approach has deepened its emotional connection with consumers and presented it with new business opportunities.In terms of“Multi-brands and Internationalization” development strategy, the business of “MUNSINGWEAR” was successfully handed over to the Group in the first half of the year. The Group plans to open its first batch of physical stores in the second half of the year. The Group has opened its first store in Malaysia, which started trial operation in May, marking a significant step in overseas expansion.For the research, development and innovation and brand marketing, the Group is committed to achieving breakthroughs in fabrics, craftsmanship and technologies by pursuing proprietary research and development across its industrial chain, with the goal of enhancing the brand's core competitive advantages. During the period, the Group’s original durable white non-iron shirts, “Water Repellent Down 3.0” and the wash-resistant polo shirts have obtained multiple certifications for their anti-wrinkle, quick-drying, and wash-resistant features, successfully driving sales growth. To step up brand transformation aiming at youth consumers, the Group has harnessed celebrity influence, collaborated with cultural IPs, and employed immersive marketing tactics to engage consumers across various age groups and city tiers.Looking ahead to the second half of 2025, the development of domestic consumer market continues to be challenging. As an industry leader, China Lilang will press on with applying its strengths, following shifts in the consumer market and technological advancement, to promote transformation and to enhance brand influence, achieving sustainable sales and profit growth.In the second half year, the Group will continue to push forward with transformation. It will continue to capitalize on the operational advantages of the DTC model in North- Eastern China, Jiangsu Province, Shandong Province and Chongqing City to achieve healthy expansion, tailoring implementation taking into account the specific conditions of each market to further achieve optimal operational performance. For the smart casual collection, which is operated entirely in the direct-to-retail mode, will have its development foundation strengthened to help maintain its strong development momentum. The Group expects the DTC model to unleash its potential further in the second half year and contribute to sales growth.On the other hand, the Group will continue to leverage the advantages of its sales channel reform, focusing on opening stores in prime locations in premium shopping malls in provincial capitals and prefecture-level cities, and closing the underperforming stores to achieve better overall store performance. At the same time, the Group will prudently expand the layout of outlet stores and increase the number of stores to speed up inventory clearance. The Group aims to achieve a net increase of 50-100 stores in 2025.To achieve both the online and offline development, the Group will accelerate its new retails business by leveraging various platforms to engage young customer groups and strengthen brand market penetration. By increasing brand exposure through multi-dimensional initiatives, the Group aims to increase online sales of new products, expecting a rise to 80% of total e-commerce sales. It will work on optimizing the respond time of its supply chain to meet customers’ needs, via including continuously upgrading its the smart logistics center.With a solid domestic foundation, the Group is confident of accelerating implementation of its “Multi-brands and Internationalization” development strategy. As a key project of its multi-brand strategy, "MUNSINGWEAR" will continue to focus on product development in the second half year to meet the needs of the new middle class for personalized, functional and sustainable fashion. For its overseas business, the Group will open more stores in Malaysia in the second half year to better tap the Malaysian market, as well as actively deploy plans to expand business coverage to other Southeast Asian markets. Furthermore, the Group will promote its brand popularity through collaboration with IPs, as well as enhancing interaction with consumers through precise social media marketing and membership programs to foster customer loyalty and capture bigger market share.Mr. Wang Dong Xing, Chairman of China Lilang, concluded: “While China's consumer market remains challenging, the Group maintains cautious optimism toward the retail sector given the government's implementation of multiple consumption-stimulus measures. The ‘LILANZ’ core collection and the ‘LESS IS MORE’ smart casual collection have both undergone innovative transformation, emerging with clearer positioning. This will enable the Group to enhance precision and efficiency in product development, design, marketing promotion and sales, and ultimately drive the long-term growth. On the other hand, as a steadfast practitioner of sustainable development, the Group has deeply embedded ESG principles into its corporate strategy, consistently driving green innovation and social shared value. During the period, we issued our first independently compiled ESG report titled "Creat a Better Life Together" and formally established an ESG Management Committee, integrating ESG governance into strategic planning and core values – demonstrating our commitment to long-term value creation. Notably, the Group achieved an MSCI ESG rating upgrade to BB, ranking among China's top menswear industry peers. Looking ahead, the Group will continue to reinforce its leadership in the domestic menswear sector and strive to achieve sustainable growth through implementing flexible marketing strategy and continuous innovation, to the ultimate end of generating greater value for shareholders, its employees and customers."About China LilangChina Lilang is one of the leading PRC menswear enterprises. As an integrated fashion enterprise, the Group designs, sources and manufactures high-quality business and casual apparel for men and sells under brands of 'LILANZ' and 'LESS IS MORE' across an extensive distribution network, mainly covering 31 provinces, autonomous regions and municipalities in the PRC. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - The highly anticipated World Humanoid Robot Games will officially open on 14 August at the Beijing National Speed Skating Oval and run through 17 August. This four-day technological extravaganza will serve as a premier showcase for the world’s most advanced humanoid robot technologies.As the world’s first large-scale comprehensive competition featuring humanoid robots as the main participants, the Games will include diverse and highly anticipated events such as running, football, street dance, martial arts, factory logistics, and hotel services. Over 100 top-tier robotics teams from around the globe will compete, fully demonstrating the application potential of humanoid robots across multiple domains. Beyond a contest of technology, the Games will be a comprehensive test of robots’ adaptability to complex environments and their ability to perform precision tasks, representing breakthroughs across AI, mechanical engineering, and other disciplines.1. Multi-Dimensional Involvement of Shoucheng HoldingsIn this year’s Games, Shoucheng Holdings acts as a capital enabler, scenario validator, and ecosystem operator. Through the management of the Beijing Robotics Industry Development Investment Fund and other industrial funds, Shoucheng has systematically invested in dozens of high-growth robotics companies, covering the entire value chain from core components to system integration, from fundamental algorithms to scenario applications. Its portfolio companies participating in the Games include Unitree Robotics, Galbot, Galaxea-AI, Noetix Robotics, Booster Robotics, and X Square Robot, each taking a leading role in core events such as football, track-and-field, combat, dance, and scenario competitions.2. Shoucheng Robotics Technology Experience Store – An Immersive Industry ShowcaseDuring the Games, the Shoucheng Robotics Technology Experience Store located inside the National Speed Skating Oval will be open to the public, displaying nearly 200 products from over 50 companies. These exhibits span smart home, education, wearable tech, and entertainment sectors. Visitors can experience cutting-edge products such as humanoid robots, smart appliances, and AI entertainment devices up close, and make on-site purchases – completing a “launch–test–sales–service” consumer loop. This initiative aligns with Shoucheng’s global “Robotics Comprehensive Experience Store” recruitment program launched in 2025, and will provide valuable operational insights for permanent experience stores planned at locations such as Rongshi Plaza.Chairman Zhao Tianyang stated that the robotics market will eventually surpass the automotive industry in scale, and that China will see the emergence of robotics companies valued at tens of billions of US dollars. Through the Games as an “industry showcase”, Shoucheng is not only presenting the technological strengths of its portfolio companies, but also validating their commercial potential in real-world environments – accelerating the journey from “lab to market.”3. Leasing Company Ensures Event DeliveryTo support training and official competitions, Beijing Robotics Leasing Company has delivered 100 designated competition robots, including 82 Booster Robotics football units, 10 Noetix Robotics track-and-field robots, and 8 Galaxea-AI robots for scenario events. All equipment has been deployed at the National Speed Skating Oval, serving training needs for football, track-and-field, and scenario competitions. The leasing company, together with manufacturer technical teams, has established an on-site service team to provide end-to-end technical support, achieving “immediate delivery, immediate service” responsiveness.Spectator EngagementTo thank its long-term supporters, Shoucheng Holdings will draw 88 lucky spectators to attend the Games in person and witness this world-class robotics competition.- Registration deadline: 14 August 2025, 9:00 a.m. (Beijing time)- Draw announcement: Before 3:00 p.m. on 14 August 2025 (Beijing time), with invitations sent via email or SMSParticipation methods:1.Fill out the registration form via: https://www.wjx.cn/vm/mfW64yI.aspx#2.Follow the official WeChat account 'Shoucheng Holdings', leave the message 'Robot Games', and complete the form via the link provided. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 11, 2025 - (ACN Newswire via SeaPRwire.com) - Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company," Stock Code: 6922.HK), a global innovator in minimally invasive interventional cryotherapy, last friday announced its unaudited interim results for the six months ended June 30, 2025. The Company demonstrated robust growth momentum and significant operational optimization during the reporting period, with key financial metrics delivering exceptional performance. Notably, its respiratory intervention product portfolio fueled a substantial revenue surge, marking accelerated commercialization progress.Respiratory Intervention Products Emerge as Core Growth Engine, Highlighting Global Competitive EdgeThe Company recorded revenue of RMB51.1 million for the first half of 2025, a 162.4% increase from RMB19.5 million in the same period of 2024, setting a new historical high. This growth was primarily attributable to the strategic focus on respiratory intervention products entering a harvest phase: The Malignant Stenosis Cryoablation System, approved by China’s National Medical Products Administration (NMPA) in March 2025, and the previously commercialized Cryoadhesion System, experienced rapid sales expansion, becoming the dominant revenue drivers. Additionally, the distribution partnership with Boston Scientific’s China affiliate, BSC International Medical Trading (Shanghai) Co., Ltd. (“BSC”), contributed significant incremental revenue from other respiratory intervention products in mainland China.Of particular significance, the Company’s Asthma Cryoablation System received "Breakthrough Medical Device" designation from the U.S. Food and Drug Administration (FDA) – the first such international recognition for a Chinese enterprise in the respiratory interventional cryotherapy field – laying a foundation for global market expansion.Cryofocus has established a highly competitive respiratory intervention portfolio addressing critical indications, including malignant stenosis, benign stenosis, asthma, chronic obstructive pulmonary disease (COPD), peri-pulmonary nodules, chronic cough, and airway tuberculosis. Among these: The Malignant Stenosis Cryoablation System has been successfully commercialized in China; systems for asthma and COPD are in confirmatory clinical trials with expected approvals in 2026; products for cough, tuberculosis, and peri-pulmonary nodules are in various R&D stages; and the Cryoadhesion System (including disposable and re-sterilizable cryoprobes) is approved and marketed. These innovations mainly stem from Cryofocus’s two core technology platforms: unique liquid nitrogen-based cryoablation technology (utilizing liquid nitrogen as the cryogenic energy source) and advanced flexible catheter technology. This integrated platform enables deep low-temperature treatment, precise control, and minimally invasive intervention, offering superior therapeutic efficacy and safety while creating significant technological barriers for competitors.Platform Value Multiplies as Multi-Segment Strategy Accelerates CommercializationCryofocus’s core value extends beyond its respiratory pipeline, underpinned by its distinction as an innovative cryotherapy platform enterprise. Leveraging its liquid nitrogen and flexible catheter technologies, the Company has successfully expanded into multiple high-potential therapeutic areas:In the vascular intervention segment: The Atrial Fibrillation (AF) Cryoablation System (for atrial fibrillation treatment) was commercialized in China in September 2024. The Cryofocus Renal Denervation (Cryo-RDN) System (for hypertension treatment), granted FDA Breakthrough Device designation, is in confirmatory clinical trials. The Pulmonary Hypertension Cryoablation System is currently in the stage of pre-clinical study. The market space for all these related cardiovascular indications is very huge.In the Natural Orifice Transluminal Endoscopic Surgery (NOTES) segment: The respiratory intervention portfolio, as detailed, is rich and leading. The cancer intervention portfolio includes the commercialized Bladder Cryoablation System; the Gastric Cryoablation System and Esophageal Cryospray System are in clinical trials targeting gastric and esophageal cancer markets.In non-cryotherapy products: Commercialized items such as the Pulmonary Nodule Localization Needle and Endoscopic Clip for Anastomosis, alongside pipeline products like the Atrial Fibrillation Pulsed Field Ablation (PFA) System and Anti-Gastroesophageal Reflux System, create complementary synergies.This "one-platform, multi-therapy" model endows Cryofocus with exceptional adaptability for indication expansion and pipeline sustainability. The Company currently boasts a robust portfolio of 23 products and candidates: 14 cryotherapy and 9 non-cryotherapy items, with 11 already commercialized. Such platform-based diversification is rare among single-therapy medical device firms, highlighting substantial long-term growth potential and risk resilience.Strong Financial Performance and Sustained Growth MomentumBeyond the revenue surge driven by respiratory products, Cryofocus’s interim results signal positive ongoing growth. The Company’s technological advantages further translated into financial resilience. Gross profit reached RMB34.3 million for the first half of 2025, up 124.5% year-on-year, with a solid gross profit margin of 67.1%. Enhanced R&D efficiency led to significantly reduced losses. R&D expenses optimized to RMB17.9 million (down 51.9% year-on-year), while the period loss narrowed 51.4% to RMB27.2 million, demonstrating a clear trend toward profitability. Cash reserves increased 40.1% from year-end 2024 to RMB63.7 million, providing a solid foundation for sustained R&D and market expansion.Revenue diversification and quality improved as high-value self-developed products (e.g., Malignant Stenosis Cryoablation System) launched and scaled, complemented by deepening collaboration with BSC. The significant reduction in R&D expenses reflects improved efficiency and reduced consumable needs as products advance, driven by optimized personnel costs and management enhancements. This establishes a sound framework for balancing innovation intensity with cost control.Furthermore, the Company increased investment in sales network development, with selling and distribution expenses rising 174.4% year-on-year to RMB9.2 million, underscoring proactive resource allocation to build marketing teams and promote newly launched products (e.g., Malignant Stenosis Cryoablation System), laying groundwork for future sales scale expansion.Global Peer Benchmark Highlights Valuation PotentialCryofocus’s technological strength in respiratory interventional cryotherapy, particularly in FDA-designated areas like asthma treatment, positions it competitively against global leaders.Benchmarked against Inspire Medical Systems (INSP) (focusing on OSA neurostimulation, differing in indication but similar in respiratory neuro-intervention): Inspire currently holds a market capitalization of US$2.279 billion and a trailing-twelve-month (TTM) P/E ratio of 44.28x. Cryofocus’s Asthma Cryoablation System similarly targets pulmonary vagal nerves via minimally invasive ablation, with an innovative pathway validated by FDA Breakthrough status. Yet, as a diversified platform innovator with a broad pipeline and multiple commercialized products, Cryofocus’s current Hong Kong market valuation (Inspire’s market cap is 12.8x Cryofocus’s) significantly trails Inspire’s.This substantial valuation gap, while influenced by factors such as differing markets (US vs. HK), stages of development (Inspire being profitable and established in the US market), and a single-product focus versus a platform model, nonetheless clearly underscores the significant upside potential in Cryofocus Medtech's current market valuation relative to its technological capabilities, the breadth of its product pipeline, and its potential for globalization breakthroughs. With the advancement of clinical progress for its respiratory intervention products (particularly the Asthma Cryoablation System COPD Cryospray System Peri-Pulmonary Nodule Cryoablation System), the clarification of overseas registration pathways, and the continued high-speed growth in its revenue scale, a market re-rating of its value represents a high-probability event. The current valuation level presents an attractive window of opportunity for investors bullish on the long-term prospects of the minimally-invasive interventional cryotherapy sector and the value inherent in a platform company model.Looking ahead, Cryofocus maintains a clear strategy: rapidly advance clinical development and commercialization of pipeline products; deepen focus on minimally invasive interventional cryotherapy while expanding the portfolio leveraging its core platforms; continuously invest in underlying and supporting technologies; and selectively expand global operations. The Company is steadily transitioning from R&D-driven to a dual-engine model integrating R&D and commercialization, advancing resolutely toward its vision of becoming a "global platform for minimally invasive interventional cryotherapy medical devices." Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 8, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels.With this label update, the previous requirement in accelerated approval stage to submit full confirmatory trial analysis to demonstrate clinical benefit has been formally removed. Additionally, data demonstrating NEFECON(R)’s efficacy in delaying kidney function decline has been included in the approved product label. IgAN is highly prevalent among Asian populations, with a 56% higher risk of progression to end-stage renal disease compared to other groups and often progresses more rapidly.Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON(R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This further demonstrates NEFECON(R)’s foundational first-line cornerstone treatment for IgAN patients."NEFECON(R) has received full approval in Taiwan, further validating its outstanding clinical value and offering physicians a more solid clinical foundation for treatment decisions.” Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said. “As the first and only fully approved etiological treatment for IgAN, NEFECON(R) has now achieved full approval across Asia. This milestone will benefit a broader patient population by enabling more individuals with IgAN to access this etiological treatment earlier, helping to slow disease progression and improve quality of life. We will continue to expand the accessibility and affordability of NEFECON(R) across Asia, aiming to benefit more IgAN patients and improve their quality of life."The approval is based on the global Phase 3 NefIgArd clinical trial, which showed that compared to placebo, it not only brought about a durable reduction in proteinuria and reduced the frequency of microscopic hematuria but also demonstrated clinically relevant and statistically significant treatment benefits in estimated glomerular filtration rate (eGFR), reducing the decline in kidney function by 50% over a period of 2 years, comprising 9 months of treatment and 15 months of observation, and potentially delaying the progression to dialysis or kidney transplantation by 12.8 years.Additionally, the complete 2-year data of the NefIgArd study further analyzed the potential differences in the response to NEFECON(R) treatment between Asians (n=83) and Caucasians (n=275). The results showed that compared to placebo, treatment with NEFECON(R) for 9 months in both Asians and Caucasians can significantly delay the decline of eGFR, protect kidney function, and bring about a sustained reduction in proteinuria and reduce the risk of microscopic hematuria.NEFECON(R) has been recommended by several authoritative treatment guidelines, including the “KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)”, and the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)". NEFECON(R) was included in China’s National Reimbursement Drug List (NRDL) in November 2024, and the supplemental application for the production expansion of NEFECON(R) has been officially approved by NMPA in August 2025.NEFECON(R) is currently the world’s first IgAN treatment to have received full approval from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency（MHRA）in the United Kingdom , as well as in other Asian territories where Everest Medicines holds the rights, including Hong Kong SAR, Macao SAR, Taiwan region (China), Singapore, and South Korea. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - On August 11, 2025, Tingyi (Cayman Islands) Holding Corp. (0322.HK, the “Company”, together with its subsidiaries, the “Group”) is pleased to announce its interim results for the six months ended 30 June 2025. In the first half of 2025, the Group remained agile in identifying and capturing growth opportunities, while maintaining a disciplined focus on its core businesses. Continued optimization of cost structures and operational efficiency supported the Group’s commitment to high-quality growth, resulting in stable performance and continued improvement across key financial indicators. For the six months ended on June 30, 2025, the Group’s revenue decreased by 2.7% year-on-year to RMB40.092 billion. Of this, the revenue from Instant Noodles was RMB13.465 billion, while the revenue from Beverages was RMB26.359 billion. Gross margin expanded by 1.9 percentage points year-on-year to 34.5%. EBITDA increased by 13.0% year-on-year to RMB5.451 billion. Driven by the improved gross margin, net profit attributable to owners of the Company increased by 20.5% year-on-year to RMB2.271 billion.Financial Summary For the six months ended 30 June RMB’00020252024ChangeRevenue40,092,16341,201,208↓ 2.7%Gross margin34.5%32.6%↑ 1.9 ppt.Gross profit of the Group13,815,03513,439,915↑ 2.8%EBITDA5,450,6374,824,605↑ 13.0%Profit for the period2,688,3042,235,065↑ 20.3%Profit attributable to owners of the Company2,271,1161,885,310↑ 20.5%Adjusted profit attributable to owners of the Company*2,111,6041,885,310↑ 12.0% Earnings per share (RMB cents) Basic40.3033.46↑ 6.84cents Diluted40.2833.46↑ 6.82centsAs at 30 June 2025, cash at bank and on hand (including long-term time deposits) was RMB19,491.373 million, representing an increase of RMB3,488.705 million when compared to 31 December 2024. Gearing ratio was -35.0%.* Adjusted profit attributable to owners of the Company include all profit attributable to owners of the Company with the exception of the one-off gain on disposal of subsidiaries. In the first half of 2025, China’s economy continued its momentum of robust development amid ongoing structural challenges. The consumer market became increasingly diversified, with consumers seeking a balance between health and enjoyment, personalization and mainstream choices, and placing greater emphasis on product quality, emotional engagement, and differentiated experiences. Purchasing patterns were characterized by “high frequency, low transaction value”. Meanwhile, instant retail channels expanded, preference-based e-commerce had become an important driver of online traffic, and discount stores and membership stores accelerated their expansion Omni-channel integration and deeper county-level penetration also emerged as key drivers of incremental demand. Against this backdrop, enterprises with sharp market insight and the ability to innovate product offerings to meet health-conscious and scenario-based demands, while achieving deep user engagement and conversion through multi-channel penetration, are vest positioned to adapt efficiently to changing market needs, enhance customer loyalty, and deliver sustainable high-quality growth.In the first half of 2025, the gross profit structure of the instant noodle business continued to improve. The revenue from Instant Noodles Business was RMB13.465 billion, accounting for 33.6% of the Group’s total revenue. During the period, the gross profit margin of Instant Noodles segment expanded by 0.7 percentage points year-on-year to 27.8%, due to product upgrades and price adjustments. As a result of this margin expansion, the profit attributable to shareholders of the Group in the Instant Noodles segment grew 11.9% year-on-year to RMB951 million in the first half of 2025.Amidst rapidly evolving consumption trends and ongoing channel transformation, the Instant Noodles business actively responded to challenges by adhering to a high-quality development philosophy. The Group achieved sustained growth by optimizing its core product categories and innovating its product portfolio. By building a multi-tiered product matrix, the business effectively met consumers' diverse demands for convenient and delicious offerings. In brand marketing, partnerships with leading IPs and a robust celebrity ambassador lineup deepened the brand’s emotional resonance with younger consumers. The business also accelerated its expansion into emerging channels such as snack wholesalers and membership stores, with differentiated products tailored to specific scenarios and market segments. As an industry pioneer, the Group was the first to introduce aerospace technology standards to noodle production, with its “Space-tech Chosen Noodles” setting new benchmarks for quality and consumer trust.The Beverages business adhered to its dual-driver development strategy of “stabilizing growth and optimizing structure”. Segment revenue reached RMB26.359 billion, accounting for 65.7% of the Group’s total revenue. During the period, the gross profit margin for Beverages grew 2.5 percentage points year-on-year to 37.7%, supported by favorable raw material costs and improved management efficiency. Driven by the improvement in gross profit margin year-on-year, the profit attributable to shareholders of the Group in the Beverages segment grew 19.7% year-on-year to RMB1.335 billion in the first half of 2025.Throughout the period, the Group continued to enhance product competitiveness and reinforce its leading position in core categories by ongoing flavor innovation, packaging upgrades and process improvements. At the same time, the Group deepened consumer insights and responded precisely to market demand, leveraging robust R&D capabilities to accelerate product upgrades and innovation. In terms of channel strategy, the Group proactively embraced diversification, establishing a comprehensive omni-channel marketing system to strengthen online and offline integration. Digital transformation continued to be a priority, with accelerated adoption of AI-driven solutions and enterprise-level data platforms, further empowering business decisions and operational efficiency while solidifying the Group’s competitive edge.Mr. Richard Chen, Chief Executive Officer, commented, “Looking into the second half of 2025, we expect government policies to continue supporting consumption and unlocking household spending potential. In this environment, the Group remains committed to implementing the strategic principle of “Consolidate, Reform and Develop”, guided by a long-term perspective and anchored in consumer needs. We will continue to deepen our focus on core businesses, drive operational excellence, and pursue sustainable, high-quality growth.On the product front, we will further optimize our portfolio and increase R&D investment to build a multi-layered, high-quality product lineup, continuously enhancing our product capabilities and competitive differentiation. In brand building, we will implement diversified marketing strategies to strengthen emotional connections with consumers, driving both brand awareness and emotional value.Operationally, we will accelerate digital transformation, prioritising the development of an enterprise-level data platform, deepening AI adoption, and building an intelligent operational system to empower business decision-making. In terms of business quality, we will continue to optimise cost structures, enhance profitability, and ensure steady and high-quality performance.We are dedicated to integrating sustainable development into our business practices, upholding our social responsibilities, and proactively seizing market opportunities to achieve synergistic growth between economic returns and social value. We are committed to delivering premium products to consumers and generous returns to shareholders. We are working with our partners to achieve our vision of a comprehensive food and beverage “National Brand” recognized by the government, trusted by partners, and preferred by consumers.”About Tingyi (Cayman Islands) Holding Corp. (0322.HK)Tingyi (Cayman Islands) Holding Corp. (the “Company”), and its subsidiaries (the “Group”) specialise in the production and distribution of instant noodles and beverages in the People’s Republic of China (the“PRC”). The Group started its instant noodle business in 1992, and expanded into instant food business and beverage business in 1996. In March 2012, the Group further expanded its beverage business by forming a strategic alliance with PepsiCo for the beverage business in the PRC. The Company exclusively manufactures, bottles, packages, distributes and sells PepsiCo soft drinks in the PRC. After years of hard work and accumulation, “Master Kong” has become one of the best-known brands among consumers in the PRC.For enquiries, please contact:Investor EnquiriesInvestor Relation Team, Tingyi (Cayman Islands) Holding Corp.E-mail: ir@tingyi.comChristensen China LimitedE-mail: stephanie.chen@christensencomms.comTel: +852 2117 0861 Copyright 2025 ACN Newswire via SeaPRwire.com.